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Research Article
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The pro-inflammatory cytokine IL-17A has been implicated in the immunopathology of
inflammatory arthritis. IL-17F bears 50% homology to IL-17A and has recently been sug-
gested to play a role in inflammation. We investigated the induction and cytokine profile
of IL-17F+ CD4+ T cells, and how IL-17F may contribute to inflammation. Upon culture of
healthy donor CD4+ T cells with IL-1β, IL-23, anti-CD3, and anti-CD28 mAb, both IL-17A
and IL-17F-expressing cells were detected. In comparison to IL-17A+IL-17F− CD4+ T cells,
IL-17F+IL-17A− and IL-17A+IL-17F+ CD4+ T cells contained lower proportions of IL-10-
expressing and GM-CSF-expressing cells and higher proportions of IFN-γ-expressing
cells. Titration of anti-CD28mAb revealed that strong co-stimulation increased IL-17F+IL-
17A− and IL-17A+IL-17F+ CD4+ T cell frequencies, whereas IL-17A+IL-17F− CD4+ T cell
frequencies decreased. This was partly mediated via an IL-2-dependent mechanism.
Addition of IL-17A, IL-17F, and TNF-α to synovial fibroblasts from patients with inflam-
matory arthritis resulted in significant production of IL-6 and IL-8, which was reduced
to a larger extent by combined blockade of IL-17A and IL-17F than blockade of IL-17A
alone. Our data indicate that IL-17A and IL-17F are differentially regulated upon T cell
co-stimulation, and that dual blockade of IL-17A and IL-17F reduces inflammation more
effectively than IL-17A blockade alone.
Keywords: interleukin-17  Th17  rheumatoid arthritis  psoriatic arthritis
 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
The IL-17 family consists of IL-17A (often referred to as IL-17),
IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. IL-17A is the best
characterized IL-17 familymember that displays pro-inflammatory
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functions and is implicated in the immunopathology of inflamma-
tory arthritis including psoriatic arthritis (PsA), axial spondylitis
(AxSpA), and to a lesser extent, rheumatoid arthritis (RA). IL-17F
shares a 50% homology to IL-17A, however the induction, func-
tion, and presence of IL-17F in health and inflammatory arthritis
is less clear.
A well-studied cellular source of IL-17A and IL-17F are CD4+
Th17 cells. In humans, TGF-β, IL-6, IL-1β, or IL-21 are required for
C© 2019 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim.
www.eji-journal.eu
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Th17 differentiation, while IL-23 is important for lineage main-
tenance and survival [1, 2]. Previous data from our laboratory
demonstrated that the frequency of IL-17A+ CD4+ T cells is sig-
nificantly increased when human memory CD4+ T cells are stim-
ulated through the TCR in the presence of in vitro or in vivo
activated monocytes [3–5]. Reports have also demonstrated that
low-strength T cell activation favors the induction of human and
mouse IL-17A+ CD4+ T cells [6, 7]. Relatively little is known
regarding the factors that drive the induction of IL-17F+ CD4+
T cells. However, it has been shown that similar to IL-17A, human
IL-17F+ CD4+ T cells are enhanced in the presence of IL-1β and
IL-23 [1].
Reports have demonstrated Th17 cells are a heterogeneous
population, including "non-pathogenic" and "pathogenic" sub-
types [8]. In mice, TGF-β and IL-6 promote the generation of
non-pathogenic Th17 cells [8], whereas exposure to IL-23 resulted
in the conversion of nonpathogenic Th17 cells to pathogenic Th17
cells [9]. Pathogenic Th17 cells are associated with a lack of IL-10
production and enhanced GM-CSF production [10]. A recent
mouse study showed that TGF-β induced higher frequencies
of IL-17F+ CD4+ T cells [11]. However, the cytokine profile
associated with IL-17F+ CD4+ T cells remains to be concluded.
IL-17A and IL-17F exert similar pro-inflammatory effects, how-
ever, IL-17A is more potent than IL-17F [12]. IL-17A and IL-17F
can induce secretion of pro-inflammatory mediators including
IL-6, IL-8, and CXCL1 from fibroblasts and epithelial cells [12, 13].
Both IL-17A [14–17] and IL-17F [14, 16, 17] can amplify their
inflammatory potential by synergizing with other cytokines
including TNF-α. In both the mouse collagen-induced arthritis
(CIA) and EAE model, blockade of IL-17F did not exhibit an effect,
whereas blockade of IL-17A reduced inflammation and disease
severity [12, 18]. Dual IL-17A and IL-17F blockade in CIA had
little additional effect compared to blockade of IL-17A alone [18].
However, in the experimental colitis mouse model neutralization
of both IL-17A and IL-17F ameliorated colitis, whereas neutraliza-
tion of IL-17A or IL-17F alone had limited effect [19]. Of relevance,
a recent report using human in vitro models suggest that dual
blockade of IL-17A and IL-17F in Th17 supernatants was more
effective at reducing the secretion of pro-inflammatory mediators
from target cells than blockade of IL-17A alone [20]. Finally,
early clinical studies with bimekizumab, a dual IL-17A and IL-17F
neutralizing antibody, have shown rapid and profound clinical
responses in psoriasis [21] and PsA [20] patients suggesting an
unappreciated role for IL-17F in addition to IL-17A in promoting
inflammation.
While IL-17A+ CD4+ T cells have been implicated in the
immunopathology of inflammatory arthritis [22–24], robust
evidence confirming the presence of IL-17F+ CD4+ T cells or
IL-17F protein is lacking. A limited number of studies have
identified the expression of IL-17F in RA and PsA synovial tissue
when compared with osteoarthritis (OA) samples via immunohis-
tochemistry analysis [14, 25]. In addition, a recent study showed
detectable levels of IL17F mRNA in six out of 14 PsA synovial tis-
sue samples [20]. A different study, however, reported that while
IL-17A protein was detected in the supernatant of stimulated RA
synovial fluid mononuclear cells, no IL-17F protein was detectable
[18].
Together these findings signify the need for a better under-
standing of the presence, function, and regulation of IL-17F.
Here, we sought to investigate what drives the induction of
IL-17F expression in CD4+ T cells, the cytokine profile of
IL-17F+ CD4+ T cells, how IL-17F may contribute to inflamma-
tion, and the presence of IL-17F and IL-17F+ CD4+ T cells in
inflammatory arthritis.
Results
Induction of IL-17F expression in human CD4+ T cells
We first sought to investigate the presence of IL-17F expressing
CD4+ T cells in human blood. Healthy control CD4+ T cells from
human blood were stimulated ex vivo for 3 h with PMA/ionomycin
in the presence of Golgi-Stop. IL-17A+ CD4+ T cells were detected
in all seven donors (ranging from 0.2 to 1.9%, Supporting Infor-
mation Fig. 1). In contrast, only low frequencies of IL-17F+ CD4+
T cells were detected (range 0.01–0.33%).
To examine factors that could induce IL-17F+ CD4+ T cells and
IL-17F secretion in vitro, we expanded on our previously published
work, which assessed the effect of LPS-activated monocytes on
IL-17A induction [3–5]. CD4+ T cells derived from healthy human
blood were co-cultured with autologous CD14+ monocytes and
stimulated with soluble anti-CD3 mAb in the absence or presence
of LPS for 3 days. Supernatants were collected for analysis of
IL-17A and IL-17F protein via ELISA, and the remaining cells re-
stimulated with PMA/ionomycin and analyzed by flow cytometry.
A representative gating strategy and fluorescence minus control
(FM) plots are shown in Supporting Information Fig. 2. In concor-
dance with our previous data, addition of LPS to T cell/monocyte
co-cultures led to a statistically significant increase in the fre-
quency of IL-17A+ CD4+ T cells (1.6-fold, P = 0.0002) as well
as in IL-17A secretion (on average 368 vs. 1389 pg/mL; 3.2-fold,
P = 0.008). LPS stimulation also resulted in a 3.4-fold increase
in IL-17F+ CD4+ T cell frequencies (P < 0.0001) and a 1.8-fold
increase in IL-17F secretion (P = 0.004; on average 137 vs. 428
pg/mL; Fig. 1A–C). In this T cell/monocyte co-culture system,
two distinct IL-17 populations were observed: IL-17A+IL-17F−
single-positive and IL-17A+IL-17F+ double-positive CD4+ T cells
(Fig. 1A).
To examine the effect of LPS addition on other cytokines,
co-culture supernatants were analyzed by Luminex. Significant
increases in IL-1β, IL-6, and IFN-γ were observed in LPS-treated
conditions (Supporting Information Fig. 3). IL-23 was also
detected at elevated levels in five of nine experiments. To
test whether IL-1β and IL-23 can drive IL-17F expression in
CD4+ T cells, bulk CD4+ T cells were cultured for 3 days with
plate-bound anti-CD3 mAb, soluble anti-CD28 mAb (replacing
the co-stimulation signal provided by CD14+ monocytes) in the
absence or presence of IL-1β and IL-23. Addition of IL-1β and
IL-23 led to a significant increase in the frequency of CD4+ T cells
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 1. LPS-activated monocytes and IL-1β and IL-23 enhance the frequencies of IL-17A+ and IL-17F+ CD4+ T cells. (A–C) Bulk CD4+ T cells (0.5 ×
106) were co-cultured 1:1 with autologous monocytes and stimulated with anti-CD3 mAb (100 ng/mL) in the absence (control) or presence (LPS) of
LPS (100 ng/mL). After 3 days cells were re-stimulated and assessed for intracellular cytokine expression by flow cytometry. (A) Representative dot
plots and (B) cumulative data show frequencies of IL-17A+ and IL-17F+ cells within the total CD4+ T cell population (12 independent experiments
using n = 17 donors in total). (C) Levels of IL-17A and IL-17F detected in culture supernatant (collected prior re-stimulation) via ELISA (data from
seven independent experiments using n = 9 donors in total). (D–F) Bulk CD4+ T cells were cultured with plate-bound anti-CD3 mAb (100 ng/mL)
and anti-CD28mAb in the absence (control) or presence of IL-1β (10 ng/mL) and IL-23 (20 ng/mL). After 3 days cells were re-stimulated and assessed
for intracellular cytokine expression by flow cytometry. (D) Representative dot plots and (E) cumulative data show frequencies of IL-17A (n = 9)
and IL-17F (n = 9) expressing cells within the total CD4+ T cell population (six independent experiments using n = 9 donors in total). (F) Cumulative
ELISA data for IL-17A and IL-17F (data from five independent experiments using n = 8 donors in total). Dashed red and blue lines indicate lower and
upper ELISA detection limits, respectively. Each connecting line represents a different donor. Data were analyzed using Wilcoxon matched-pairs
signed rank test.
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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expressing IL-17A (1.7-fold, P = 0.004) and/or IL-17F (3.7-fold,
P = 0.004; Fig. 1D and E), as well as significant increases in
IL-17A (on average 1068 vs. 2972 pg/mL; 2.8-fold, P = 0.008)
and IL-17F protein levels (on average 1962 vs. 6788 pg/mL;
3.5-fold, P = 0.008; Fig. 1F). In this T cell culture system, three
distinct IL-17 populations were observed: IL-17A+IL-17F− single-
positive, IL-17A+IL-17F+ double-positive, and IL-17F+IL-17A−
single positive CD4+ T cells (Fig. 1D).
CD28 co-stimulation and high-dose anti-CD3 mAb
enhance induction of IL-17F+ CD4+ T cells
To investigate the contribution of CD28 co-stimulation to the
induction of IL-17F+ CD4+ T cells, healthy peripheral blood bulk
CD4+ T cells were cultured with plate-bound anti-CD3mAb, IL-1β,
and IL-23 in the absence or presence of 1 μg/mL anti-CD28 mAb
for 3 days. Addition of anti-CD28 mAb had no effect on the fre-
quency of total IL-17A+ CD4+ T cells, while significantly increasing
the frequency of total IL-17F+ CD4+ T cells (Fig. 2A). To assess the
effect of anti-CD3 mAb stimulation, bulk CD4+ T cells were cul-
tured with IL-1β, IL-23, and anti-CD28 mAb with either low (0.15
μg/mL) or high (5 μg/mL) doses of plate-bound anti-CD3 mAb.
While no effect in percentage of IL-17A+ CD4+ T cells with low
versus high doses of anti-CD3 mAb was observed, high dose anti-
CD3 mAb significantly increased the frequency of IL-17F+ CD4+
T cells (Fig. 2B).
We extended these observations by titrating anti-CD28 and
anti-CD3 mAbs into CD4+ T cell cultures, in presence of IL-1β
and IL-23. Titration of anti-CD28 mAb led to a dose-dependent
decrease in the percentage of IL-17A+IL-17F− CD4+ T cells, while
increasing IL-17A+IL-17F+ and IL-17F+IL-17A− CD4+ T cells
(Fig. 2C and D). Titration of anti-CD3 mAb also increased the
frequency of IL-17A+IL-17F+ and IL-17F+IL-17A− CD4+ T cells
in a dose-dependent manner (Fig. 2E and F). When examining
cytokine secretion in cell culture supernatants, titration of anti-
CD28 mAb led to a dose-dependent increase in both IL-17A and
IL-17F protein secretion (Supporting Information Fig. 4A). Similar
results were observed with titration of anti-CD3 mAb (Supporting
Information Fig. 4B). Higher levels of IL-17F versus IL-17A were
detected, although this should be interpreted with caution as dif-
ferent ELISA antibody affinities make it difficult to draw compar-
isons between levels of different cytokines.
The increase in IL-17A secretion was unexpected as our flow
cytometry data suggested IL-17A expression remained unchanged
with higher doses of anti-CD28 mAb or anti-CD3 mAb. This result
could be due to the kinetics of the assay and reflect accumulation
of IL-17A secreted in the early stages of CD4+ T cell activation. To
investigate the kinetics of IL-17A and IL-17F expression fromCD4+
T cells, healthy control CD4+ T cells were cultured with plate-
bound anti-CD3 and soluble anti-CD28 for various time points
(0–80 h) followed by culture for 3 h in the presence of brefeldin.
As shown in Supporting Information Fig. 5, IL-17A appears to
peak at the early stages of CD4+ T cell activation, while IL-17F
expression shows a more gradual increase, with high expression
observed at the later stages of CD4+ T cell activation.
CD28-driven induction of IL-17F+ CD4+ T cells is
mediated in part by IL-2
Given that CD28 signaling is a strong enhancer of IL-2 production
by CD4+ T cells [26], we hypothesized that the CD28-driven
increase in IL-17F+ CD4+ T cells was mediated by IL-2. As
expected, titration of anti-CD28 mAb led to a dose-dependent
increase in IL-2 in culture supernatants (Fig. 3A). To assess the
role of IL-2 in promoting IL-17F+ CD4+ T cells, CD4+ T cell
cultures derived from healthy peripheral blood were stimulated
with anti-CD3 mAb, anti-CD28 mAb, IL-1β, and IL-23, in the
absence or presence of neutralizing anti-IL-2 mAb. No significant
changes in total IL-17A+ CD4+ T cell frequencies were observed
in the absence or presence of anti-CD28 mAb with or without IL-2
blocking antibody (Fig. 3B). In contrast, and as we observed in
Fig. 2, addition of anti-CD28 mAb promoted total IL-17F+ CD4+
T cell frequencies (approximately 1% vs. 1.7% in absence vs.
presence of anti-CD28 mAb), and this effect was in part abrogated
by IL-2 blockade. Similarly, IL-2 blockade significantly reduced
the anti-CD28 mAb mediated increase in IL-17A+IL-17F+ and
IL-17F+IL-17A− CD4+ T cells (Fig. 3C). Addition of an iso-
type control Ab did not affect the percentage of CD4+ T cells
expressing IL-17A or IL-17F (Supporting Information Fig. 6).
Collectively, these data indicate that CD28 signaling promotes
IL-17F expression in CD4+ T cells, which is in part mediated via
an IL-2 dependent mechanism.
Investigating the effect of IL-17A and IL-17F addition
versus blockade on synovial fibroblasts
To assess the functional role of IL-17F, RA and PsA fibroblasts
were incubated for 24 h with human recombinant IL-17A,
IL-17F, IL-17AF, TNF-α, or vehicle controls at the indicated
concentrations. Recombinant IL-17A, IL-17F, IL-17AF, or TNF-α
all induced a dose-dependent increase in IL-6 and IL-8 secretion
by fibroblasts (Fig. 4A). In agreement with literature, a hierarchy
in inflammatory potency of the IL-17 cytokines was observed:
IL-17A elicited higher levels of IL-6 and IL-8 in comparison to
IL-17F, while IL-17AF induced intermediate IL-6 and IL-8 levels.
In general, TNF-α induced higher levels of IL-6 and IL-8, although
at 50 ng/mL IL-17A and TNF-α induced similar levels of IL-6. We
investigated whether combinations of IL-17A, IL-17F, IL-17AF,
and TNF-α further enhanced the secretion of inflammatory
cytokines. The combination of IL-17A and TNF-α resulted in a
synergistic increase in IL-6 and IL-8 secretion compared with
addition of IL-17A or TNF-α alone (Fig. 4B). Similarly, synergistic
responses were observed between TNF-α and IL-17F, and TNF-α
and IL-17AF. Addition of IL-17F or IL-17AF to IL-17A and TNF-α
did not lead to further additive or synergistic effects on IL-6 or
IL-8 secretion by fibroblasts (Fig. 4C).
To further investigate the functional impact of an environment
in which both IL-17A and IL-17F are present, we assessed the
effect of dual IL-17A and IL-17F blockade in this reductionist sys-
tem. IL-17A, IL-17F, IL-17AF, and TNF-α were added to RA or
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. CD28 co-stimulation and high-dose anti-CD3 mAb enhance induction of IL-17F+ CD4+ T cells. (A) Bulk CD4+ T cells were cultured with
anti-CD3 mAb, IL-23, and IL-1β in the absence or presence of anti-CD28 mAb (1 μg/mL). After 3 days, cells were re-stimulated and assessed for
IL-17A and IL-17F cytokine expression via flow cytometry. Results show the cumulative data for IL-17A+ and IL-17F+ CD4+ T cells (four independent
experiments using n = 9 donors in total) analyzed using a Wilcoxon-matched pairs test. (B) Bulk CD4+ T cells were cultured with anti-CD28 mAb,
IL-23, and IL-1β in the presence of low (0.15 μg/mL) or high (5 μg/mL) dose anti-CD3 mAb for 3 days and then re-stimulated. Results show the
cumulative flow cytometric data for IL-17A+ and IL-17F+ CD4+ T cells (three independent experiments using n = 8 donors in total) analyzed using
a Wilcoxon-matched pairs test. Bulk CD4+ T cells were cultured with (C and D) anti-CD3 mAb, IL-23, and IL-1β in the presence of increasing doses
of anti-CD28 mAb (0–2 μg/ml) or (E and F) anti-CD28 mAb, IL-23, and IL-1β in the presence of increasing doses of plate-bound anti-CD3 mAb (0–5
μg/mL). After 3 days, cells were re-stimulated and assessed for IL-17A and IL-17F cytokine expression. (C and E) Representative dot plots show the
percentages of IL-17A+IL-17F−, IL-17A+IL-17F+, and IL-17F+IL-17A− cells within CD4+ T cells and (D and F) box whisker plots represent cumulative
data from (D) three independent experiments using n = 6 donors in total and (F) three independent experiments using n = 8 donors in total. Data
are shown as the mean ± SEM. Statistical analysis was performed using Friedman test with comparison to control (0 μg/mL for anti-CD28 mAb
and 0.15 μg/mL for anti-CD3 by Dunn’s Multiple Comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2020. 50: 568–580 Immunodeficiencies and autoimmunity 573
Figure 3. CD28-driven induction of IL-17F+
CD4+ T cells is mediated in part by IL-2.
Bulk CD4+ T cells were cultured with anti-
CD3 mAb, IL-23, and IL-1β in the presence
of increasing doses of anti-CD28 mAb (0–
2 μg/mL). (A) After 3 days, culture super-
natant was collected and levels of IL-2
protein were analysed by ELISA (cumula-
tive data from three independent experi-
ments from n = 4 donors in total). Data are
shown as the mean ± SEM. Dashed red line
indicates the lower ELISA detection limit,
respectively. (B) Bulk CD4+ T cells were cul-
tured with anti-CD3 mAb, IL-23, and IL-1β
in the absence or presence of anti-CD28
mAb and anti-IL-2 mAb for 3 days. Graphs
show cumulative data of the frequencies
of total IL-17A+ and IL-17F+ CD4+ T cells
(B) or IL-17A+IL-17F−, IL-17A+IL-17F+, and
IL-17F+IL-17A− CD4+ T cells (C) (data from
five independent experiments using n = 8
donors in total). Statistical analysis was
performed using Friedman test with com-
parison to all samples by Dunn’s Multiple
Comparisons test.
PsA synovial fibroblasts in the presence of IL-17A, IL-17F, or dual
IL-17A/IL-17F blocking antibodies. Anti-TNF-α mAb and human
IgG1 isotype control were added as positive and negative con-
trol, respectively. As before, addition of the cytokine cocktail led
to an increase in IL-6 and IL-8 production by fibroblasts in com-
parison to medium alone. Addition of isotype control or anti-IL-
17F blocking antibody had no effect on IL-6 or IL-8 production.
In contrast, IL-6 and IL-8 secretion was reduced upon addition
of IL-17A blocking antibody, and cytokine production was fur-
ther reduced upon combined blockade of IL-17A and IL-17F using
bimekizumab (Fig. 4D). When compared directly, dual IL-17A and
IL-17F blockade reduced IL-6 and IL-8 levels significantly more
than IL-17A blockade alone (Fig. 4E). TNF-α blockade reduced
IL-6 to similar levels as bimekizumab but was more effective at
reducing IL-8 levels. We also measured the levels of additional
pro-inflammatory mediators, CXCL1, CXCL5, and CCL20 in the
fibroblast supernatant by Luminex (Fig. 4F). Similar to IL-6 and
IL-8, dual neutralization of IL-17A and IL-17F reduced the pro-
duction of these chemokines by fibroblasts further than IL-17A
blockade alone. Collectively, these data suggest that a combined
blockade of IL-17A and IL-17F is more effective at reducing inflam-
mation than blockade of IL-17A alone.
IL-17A and IL-17F expressing CD4+ T cells display
different cytokine profiles
We next assessed the co-expression of TNF-α, IFN-γ, GM-CSF, and
IL-10 in IL-17A+ and IL-17F+ populations upon 3-day stimulation
of bulk CD4+ T cells with anti-CD3 mAb, anti-CD28 mAb, IL-1β,
and IL-23. IL-17A+IL-17F−, IL-17A+IL-17F+, and IL-17F+IL-17A−
CD4+ T cells displayed similarly high frequencies of cells express-
ing TNF-α (Fig. 5A and B). When compared to IL-17A+IL-17F−
CD4+ T cells, IL-17F+IL-17A− CD4+ T cells displayed significantly
higher frequencies of IFN-γ expressing cells (approximately 34%
vs. 52%, respectively) and significantly lower frequencies of IL-10
expressing cells (approximately 4.6% vs. 0.9%, respectively).
IL-17A+IL-17F− displayed a significantly higher percentage of
cells co-expressing GM-CSF versus IL-17F+IL-17A− (approxi-
mately 8% vs. 1.9%, respectively). IL-17A+IL-17F+ CD4+ T cells
displayed intermediate co-expression levels for IFN-γ, IL-10, and
GM-CSF (approximately 50%, 1.4% and 4.8%, respectively).
These data indicate that IL-17A+ and IL-17F+ CD4+ T cells
display different cytokine profiles.
We further investigated whether IL-17F+ CD4+ T cells show a
Th1 bias by comparing the expression of the transcription factor
T-bet, in IL-17F+ versus IL-17A+ CD4+ T cells. However, our data
showed no consistent difference in the expression of T-bet across
the different IL-17 populations (Supporting Information Fig. 7).
Presence of IL-17F+ CD4+ T cells in inflammatory
arthritis
Our final aim was to investigate the presence of IL-17F+ CD4+
T cells and IL-17F protein in the blood and inflamed joints of
patients with RA or PsA. Paired peripheral bloodmononuclear cells
(PBMCs) and synovial fluidmononuclear cells (SFMCs) fromRA or
PsA patients were stimulated ex vivo with PMA/ionomycin. When
gated within CD3+ CD4+ T cells, IL-17A expressing cells were
increased in the synovial fluid (SF) compared to the peripheral
blood (PB) of patients with inflammatory arthritis (IA). In contrast,
very few IL-17F+ CD4+ T cells were detected in matched PB and
SF samples from IA patients (Fig. 6A and B). We investigated the
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
574 Lachrissa A. Burns et al. Eur. J. Immunol. 2020. 50: 568–580
Figure 4. Investigating the effect of IL-17A and IL-17F addition versus blockade on synovial fibroblasts. (A) Synovial fibroblasts were cultured
with indicated concentrations of IL-17A, IL-17F, and TNF-α. The levels of IL-6 and IL-8 present in the fibroblast supernatant were measured by
ELISA (cumulative data from four independent experiments using in total n = 3 RA fibroblasts and n = 1 PsA fibroblasts). Data are shown as
the mean ± SEM. (B and C) Combinations of the above cytokines (IL-17 cytokines at 10 ng/mL and TNF-α at 1 ng/mL) were added to synovial
fibroblasts. After 24 h incubation, supernatants were collected and IL-6 (cumulative data from six independent experiments using in total n = 3
RA fibroblasts and n = 5 PsA fibroblasts) and IL-8 (cumulative data from five independent experiments using in total n = 2 RA fibroblasts and n = 5
PsA fibroblasts) secretion levels were measured by ELISA. Bars show mean ± SEM of results. Statistical analysis was performed using Friedman
test with comparison to IL-17A and TNF-α by Dunn’s Multiple Comparisons test. (D–F) Synovial fibroblasts were cultured with a cocktail of human
recombinant IL-17A, IL-17F, IL-17AF, and TNF-α (all at 10 ng/mL) in the absence or presence of the indicated neutralizing antibodies (1 μg/mL).
After 24 h incubation, supernatants were collected and IL-6 (cumulative data from 10 independent experiments using in total n = 4 RA fibroblasts
and n = 6 PsA fibroblasts) and IL-8 (cumulative data from four independent experiments using in total n = 3 RA fibroblasts and n = 3 PsA fibroblasts)
secretion levels were measured by ELISA. In general, two different RA and PsA cell lines were used in each experiment. (D) Bars showmean ± SEM
of results. Statistical analysis was performed using Friedman test with comparison to isotype by Dunn’s Multiple Comparisons test. (E) Analysis
of IL-6 and IL-8 protein levels conditioned either with αIL-17A or αIL-17A + αIL-17F using a Wilcoxon-matched pairs test. (F) Synovial fibroblast
supernatants (one independent experiment using n = 2 PsA fibroblasts and n = 1 RA fibroblasts) were analyzed for levels of CXCL1, CXCL5, and
CCL20 via Luminex. Bars show mean ± SEM of results. Dashed red and blue lines indicate lower and upper ELISA detection limits, respectively.
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Figure 5. IL-17F+IL-17A− and IL-17A+IL-17F+ CD4+ T cells display a different cytokine profile in comparison to IL-17A+IL-17F− CD4+ T cells.
Bulk CD4+ T cells were cultured with anti-CD3 mAb, anti-CD28 mAb, IL-23, and IL-1β. After 3 days, cells were re-stimulated and assessed for
intracellular cytokine expression by flow cytometry. (A) Representative dot plot of IL-17A+ and IL-17F+ CD4+ T cell populations. Following gating
within IL-17A−IL-17F−, IL-17A+IL-17F, IL-17A+IL-17F+, and IL-17F+IL-17A− CD4+ T cells, the co-expression of other cytokines was analyzed. (B)
Cumulative data showing the percentage of each population co-expressing TNF-α (four independent experiments using n = 6 donors in total),
IFN-γ (five independent experiments using n = 8 donors in total), GM-CSF (three independent experiments using n = 7 donors in total), or IL-10
(six independent experiments using n = 8 donors in total). Bars represent the mean ± SEM. Statistical analysis was performed using Friedman test
with comparison to IL-17A+IL-17F− CD4+ T cells by Dunn’s Multiple Comparisons test.
presence of IL-17A and IL-17F protein in paired serum and SF
from patients with IA, and in serum from healthy controls and
serum and SF from osteoarthritis patients as controls. In line with
previous studies [23, 27], IL-17A protein was detected at increased
concentrations in the SF versus serum of IA patients, while no IL-
17A protein was detectable in healthy control serum or paired
serum or SF from patients with osteoarthritis. In contrast, IL-17F
was undetectable or present at very low levels in both serum and
SF samples (Fig. 6C). Increasing the ex vivo stimulationwith either
PMA and ionomycin or anti-CD3 mAb and anti-CD28 mAb did not
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Figure 6. Investigating the presence of IL-17A+ and IL-17F+ CD4+ T cells in inflammatory arthritis. (A–C) Matched PBMC and SFMC from RA and
PsA donors were stimulated for 3 h with PMA and ionomycin and then assessed for intracellular IL-17A and IL-17F cytokine expression by flow
cytometry. Representative dot plots (A) and cumulative data (B) show frequencies of IL-17A and IL-17F expressing cells within the total CD4+ T cell
population of matched PBMC and SFMC from RA (black symbols) and PsA (grey symbols). Data show 12 independent experiments using n = 8 RA
donors and n = 6 PsA donors in total. (C) In one independent experiment, serum from healthy controls (n = 2) and paired serum and synovial fluid
from OA patients (n = 2), RA patients (n = 7), and PsA patients (n = 6) were analyzed by ELISA for protein levels of IL-17A and IL-17F. Dashed red
and blue lines represent the lower and upper ELISA detection limits, respectively. (D and E) Paired PBMC and SFMC samples from patients with
RA (black symbols) or PsA (grey symbols) were cultured with plate-bound anti-CD3 mAb, anti-CD28 mAb, IL-1β, and IL-23. After 3 days incubation,
cells were re-stimulated for 3 h with PMA and ionomycin. Representative dot plots and (D) cumulative data (E) showing the presence of IL-17A
or IL-17F expressing cells. Data show 6 independent experiments with n = 4 RA donors and n = 3 PsA donors in total. Data were analyzed using
Wilcoxon matched-pairs test.
reveal any significant increase in IL-17F+ CD4+ T cell frequencies
(n = 2, data not shown).
Although we did not detect IL-17F, we did detect IL-1β and
IL-23 at elevated levels in the majority of SF versus serum samples
of patients with RA or PsA (Supporting Information Fig. 8). We
tested whether stimulating RA or PsA PBMC and SFMC in vitro
with anti-CD3 and CD28 mAbs in the presence of IL-1β and IL-23
would induce IL-17F+ CD4+ T cells. Culturing PBMC and SFMC
under these conditions revealed clearly detectable frequencies of
IL-17F expressing CD4+ T cells (both single and double positive;
Fig. 6D and E). There was no consistent difference in the frequen-
cies of IL-17A or IL-17F-expressing CD4+ T cells between cells
derived from the synovial fluid or the peripheral blood.
Discussion
Our findings demonstrate that high-strength T cell stimulation
drives IL-17F expressing CD4+ T cells and that IL-17A and IL-17F
are differentially regulated. In line with previous studies, we show
that the pro-inflammatory functions of IL-17F are enhanced in the
presence of TNF-α and that in an environment in which IL-17A,
IL-17F, and TNF-α are present, dual IL-17A and IL-17F blockade is
more effective at reducing inflammatory cytokine production than
blockade of IL-17A alone.
Expanding upon our previous work [3–5], we show that LPS
addition to CD4+ T cell/ CD14+ monocyte co-cultures leads
to an increase in the percentage of both IL-17A+ and IL-17F+
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CD4+ T cells. Although in this study the mechanism by which
LPS-activated monocytes induce IL-17F+ CD4+ T is not fully
elucidated, we show that IL-1β and IL-23 are likely to play a
role. When comparing induction of IL-17F+ CD4+ T cells by
LPS-activated monocytes versus soluble anti-CD28 mAb and
recombinant IL-1β and IL-23, we observed that while both
cultures induced IL-17A+IL-17F+ CD4+ T cells, only the latter
culture resulted in IL-17F+IL-17A− CD4+ T cells. We postulate
that the anti-CD28 mAb elicits a stronger co-stimulation signal
than the LPS-activated monocytes, which drives the induction
of IL-17F+IL-17A− CD4+ T cells. Indeed, we demonstrate that
addition of anti-CD28 mAb to CD4+ T cell cultures significantly
increases the frequency of IL-17F+ CD4+ T cells. Furthermore,
we show that high-strength rather than low strength anti-CD3
stimulation favors induction of IL-17F+ CD4+ T cells. These
data indicate that high-strength T cell stimulation drives the
induction of human IL-17F+ CD4+ T cells. To the best of our
knowledge, this has not been previously reported. It has been
shown that high-strength stimulation decreased IL-17A+ CD4+
T cell frequency [7]. Additionally, a mouse study demonstrated
that anti-CD28 mAb suppressed the differentiation of IL-17A+
CD4+ T cells in an IL-2 and IFN-γ dependent mechanism [6].
Under our culture conditions, we did not observe a consistent
decrease in the frequency of total IL-17A+ CD4+ T cells upon
addition of higher doses of anti-CD28 mAb or anti-CD3 mAb.
We demonstrate that the anti-CD28 mAb mediated induction
of human IL-17F+ CD4+ T cells is in part mediated by IL-2. In con-
trast, IL-2 blockade did not lead to consistent differences in the fre-
quency of human IL-17A+ CD4+ T cells. Differential effects of IL-2
on IL-17A and IL-17F regulation have been previously reported in
mice [28], however the results differ to those reported here. Using
mouse cells, Yang et al. demonstrated that in the presence of high
levels of IL-6, IL-2 addition decreased the percentage of IL-17A+
CD4+ T cells, while not affecting the frequency of IL-17F+ CD4+
T cells [28]. While no further studies report on the effect of IL-2 on
IL-17F+ CD4+ T cell induction, numerous mouse studies demon-
strate that IL-2 downregulates IL-17A+ CD4+ T cells [6, 28–31].
One explanation for our contrasting results could be that IL-2
affects IL-17A and IL-17F in humans differently. Furthermore, we
assessed the effect of IL-2 on IL-17A+ CD4+ T cells induced from
bulk CD4+ T cell cultures, while the mouse studies used na¨ıve
CD4+ T cell polarization protocols [28, 29]. Our data indicate
that IL-17A and IL-17F are differentially regulated, at least in
vitro, thus supporting previous evidence of differential regulation
of IL-17A and IL-17F [32, 33].
Our findings show that IL-17A+IL-17F−, IL-17A+IL-17F+, and
IL-17F+IL-17A− CD4+ T cells display different cytokine profiles;
IL-17F+IL-17A− (and to a lesser extent IL-17F+IL-17A+) CD4+
T cells displayed lower frequencies of IL-10 and GM-CSF and
higher frequencies of IFN-γ when compared with IL-17A+IL-17F−
CD4+ T cells. To the best of our knowledge, the cytokine pro-
file of the different IL-17A/IL-17F CD4+ T cell populations has
not been characterized previously. Aschenbrenner et al. recently
performed RNA-seq on human Th17-IL-10− and Th17-IL-10+
clones. Interestingly, IL17F and IFNG were highly expressed in
Th17-IL-10− cells associated with a "pathogenic" Th17 subtype,
whereas IL17A was preferentially expressed in Th17-IL-10+ cells
associated with a "nonpathogenic" Th17 phenotype. Function-
ally, Th17-IL-10− cells had the ability to polarise monocytes
into an inflammatory M1 phenotype, while Th17−IL-10+ cells
induced an M2 anti-inflammatory phenotype [34]. Collectively,
our work and other studies [11, 34] highlight that perform-
ing molecular and functional characterization of isolated IL-17A/
IL-17F CD4+ T cell sub-populations would be an interesting
avenue to pursue.
Our data show, in line with other studies [14], that IL-17F
induces IL-6 and IL-8 secretion from synovial fibroblasts that is
enhanced in the presence of TNF-α. However, in comparison with
IL-17A and IL-17AF, IL-17F is the least potent. Our blocking exper-
iments revealed that while blockade of IL-17F alone has no effect
on cytokine secretion, dual IL-17A and IL-17F blockade by bimek-
izumab is more effective at reducing IL-6, IL-8, CXCL1, CXCL5,
and CCL20 secretion by fibroblasts compared to blockade of
IL-17A alone. These data show that in the presence of IL-17A,
IL-17F has a limited effect on fibroblasts. However, in the absence
of IL-17A, IL-17F can synergize with TNF-α and elicit a signifi-
cant inflammatory response. Collectively, our data support pre-
vious studies [19, 20] and demonstrate that in an environment
in which both IL-17A and IL-17F are present, dual IL-17A and
IL-17F blockade may reduce inflammation to a greater extent.
Recent clinical studies have shown that dual IL-17A and IL-17F
blockade by bimekizumab results in rapid and profound efficacy
in the treatment of PsA [20] and psoriasis [21]. However, in the
absence of data from direct head-to-head studies, it remains to be
concluded whether in these diseases there is a clinically superior
effect of dual IL-17A and IL17F blockade versus blockade of IL-17A
alone.
In agreement with previous studies [22–24, 27], we demon-
strate the presence of IL-17A+ CD4+ T cells and IL-17A protein
at elevated levels in the synovial fluid versus blood from patients
with RA or PsA. In contrast, few IL-17F+ CD4+ T cells were
detected in the PB or SF of inflammatory arthritis patients, and
ELISA results showed IL-17F to be undetectable or present at very
low levels in inflammatory arthritis paired serum and SF samples.
Current literature shows discrepancies regarding the presence
of IL-17F in SF from inflammatory arthritis patients [18, 35]. In
addition, a recent report by Kolbinger et al. detected levels of
IL-17F and IL-17A in the serum of PsA, AS, and psoriasis patients
using a highly sensitive Singulex immunoassay. That study
suggested IL-17F is present at higher levels than IL-17A [36].
Inconsistencies across studies in levels of IL-17F levels detected
in patient samples may be due to differences in the specific
assay method, differences in sampling preparation or heterophilic
antibody interference [37]. In summary, while our data easily
detect IL-17A+ CD4+ T cells and IL-17A protein in inflammatory
arthritis SF, we do not confirm the presence of IL-17F+ CD4+
T cells or IL-17F protein in inflammatory arthritis. However, our
in vitro stimulation cultures demonstrate that CD4+ T cells from
the PB and SF of patients with inflammatory arthritis have the
capacity to express IL-17F given a suitable environment.
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Collectively, our data indicate that high-strength T cell stim-
ulation induces IL-17F expressing CD4+ T cells and that IL-17A
and IL-17F are differentially regulated. Moreover, we show that
the cytokine profile of IL-17F+ CD4+ T cells differs from IL-17A+
CD4+ T cells, highlighting the need to further characterize these
IL-17-expressing sub-populations. Finally, our data demonstrate
that dual neutralization of IL-17A and IL-17F may be more effec-
tive at reducing inflammation than blockade of IL-17A alone. This
may be beneficial in alleviating symptoms of inflammatory dis-
eases in which both IL-17A and IL-17F are present.
Materials and methods
Cell isolation
Peripheral blood samples were collected from healthy adult vol-
unteers and peripheral blood or synovial fluid samples from
patients with RA or PsA attending the Guy’s Hospital Rheumatol-
ogy Department (Research Ethics Committee Ref 06/Q0705/20).
Patient cohort information is provided in Supporting Information
Tables 1 and 2. PBMCs or SFMCs were isolated via density gra-
dient centrifugation using Lymphoprep (Axis-Shield, Oslo, Nor-
way). CD14+ monocytes were isolated by positive selection using
CD14 microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany;
average purity 95%) and CD4+ T cells were isolated by negative
depletion (Miltenyi Biotec; average purity 97%).
RA and PsA fibroblast cell lines were either generated in-
house or received as a kind gift from Dr. Anca Catrina (Karolin-
ska University Hospital, Sweden). In-house fibroblast cell lines
were obtained from RA or PsA synovial membrane tissue sam-
ples, collected via arthroscopic biopsy from the joint (REC refs
17/LO/1940 and 07/H0809/35). Synovial tissue samples were
cut into 1mm3 pieces and individually incubated at 37°C with 5%
CO2 in a well coated with 0.1% bovine gelatin (Sigma–Aldrich,
Missouri, USA) and supplemented with DMEM (ThermoFisher Sci-
entific, Massachusetts, USA) with 20% FCS, 100 units/mL peni-
cillin, 100 μg/mL of streptomycin, 2% glutamine, and fungizone
(all ThermoFisher Scientific). Tissue explants were cultured until
synovial fibroblasts had grown out of the synovial tissue. Cells
were passaged when they reached 80% confluence in T175 flasks.
Fibroblast lines were used between passage 2 and 8.
Cell-free serum and synovial fluid samples
For serum samples, blood was collected in a no additive serum
tube (Fisher Scientific, Loughborough, UK) and stored at 4°C for
1 h before centrifugation at 1200 rpm for 10 min and serum
harvesting. Synovial fluid was centrifuged for 10 min at 1200 rpm
after which the cell-free fluid was removed. Serum from healthy
controls (n = 2) and paired serum and synovial fluid from OA
patients (n = 2), RA patients (n = 7), and PsA patients (n = 6)
were stored at −80°C.
CD4+ T cell or mononuclear cell cultures
Human PBMCs or SFMCs were cultured in Roswell Park Memo-
rial Institute media (RPMI) 1640 (Gibco, Invitrogen, UK) sup-
plemented with 10% FCS, 100 units/mL penicillin, 100 μg/mL
of streptomycin, and 1% glutamine. Freshly isolated bulk CD4+
T cells (0.5 × 106) were co-cultured for 3 days at a 1:1 ratio
with autologous CD14+ monocytes in a 48-well plate with 100
ng/mL soluble anti-CD3 mAb (clone OKT3, Janssen Cilag, High
Wycombe, UK or Biolegend, Cambridge, UK) in the absence or
presence of 100 ng/mL LPS (Sigma–Aldrich). In some experi-
ments, 1 × 106 isolated CD4+ T cells were cultured with plate-
bound anti-CD3 mAb (1.25 μg/mL) in the absence or presence
of soluble anti-CD28 mAb (1 μg/mL, R&D Systems, Minneapolis,
USA), human recombinant IL-1β (10 ng/mL, Peprotech, London,
UK) and IL-23 (20 ng/mL, R&D, UK) with or without neutralizing
anti-human IL-2 mAb (1 μg/mL, goat IgG, R&D) or isotype control
mAb (goat IgG, BD Biosciences, San Jose, USA). Some experiments
involved titrating soluble anti-CD28 mAb (0–2 μg/mL) or plate-
bound anti-CD3 mAb (0–5 μg/mL). For PBMC and SFMC cultures,
1× 106 cells were cultured with plate-bound anti-CD3 and soluble
anti-CD28 mAb in the absence or presence of IL-1β (10 ng/mL)
and IL-23 (20 ng/mL).
Fibroblast cultures
For fibroblast assays, 10 × 103 fibroblasts were seeded per well
in a 96 well flat-bottom plate in DMEM culture medium and
incubated for 24 h at 37 °C with 5% CO2. Following supernatant
removal, recombinant human cytokines IL-17A, TNF-α (both from
Miltenyi Biotec), IL-17F, or IL-17AF (both from R&D) were added
either individually or in combination at the indicated concen-
trations. After 24 h, fibroblast supernatants were collected and
protein levels analyzed by ELISA. Blocking antibodies (1 μg/mL)
included anti-IL-17A mAb (targeting both the IL-17A homodimer
and IL-17AF heterodimer), anti-IL-17F (targeting the IL-17F
homodimer only), and bimekizumab (targeting IL-17A, IL-17F,
and IL-17AF; all human IgG). These IL-17 blocking antibodies
were generated in-house by UCB Pharma and characterized
previously [20]. For TNF-α blockade, adalimumab (human IgG1,
Abbott Laboratories, Chicago, IL, USA) was used. Human IgG1
(UCB in-house) was used as isotype control.
Flow cytometry
For ex vivo analysis, 1 × 106 PBMC, SFMC, or CD4+ T cells were
cultured for 3 h in the presence of PMA; 50 ng/mL, Sigma–
Aldrich), ionomycin (750 ng/mL, Sigma–Aldrich), and Golgi-
Stop (monensin, according to manufacturer’s guidelines, BD Bio-
sciences). Similarly, following in vitro culture, cells were stimu-
lated for 3 hours with PMA, ionomycin and Golgi-Stop. In some
in vitro experiments, PMA (10 ng/mL), ionomycin (1 μg/mL),
and brefeldin (10 μg/mL) (Sigma–Aldrich) were used. To gate
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for live CD4+ T cells, cells were labeled with a fixable viability
dye (eFluor506 or eFluor780, eBioscience, San Diego, CA, USA),
anti-CD14 and/or CD8 mAbs before fixing in 2% paraformalde-
hyde (Merck & Co.,Inc., Kenilworth, NJ, USA), and permeabiliza-
tion with 0.5% saponin (Sigma–Aldrich). Cells were then stained
intracellularly with combinations of antibodies (Supporting Infor-
mation Table 3). Cells were acquired using a FACSCantoII or
LSR Fortessa (BD Biosciences). Flow cytometry data were ana-
lyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Cytokine co-expression analysis was performed only when the
event count within the IL-17A+ or IL-17F+ population exceeded
300. All experiments adhered to guidelines for the use of flow
cytometry in immunological studies [38].
Cytokine detection
Primary cell culture supernatants were analyzed using ELISA kits
for IL-17A (Biolegend or eBioscience), IL-17F (eBioscience), IL-2,
or IFN-γ (both from Biolegend). In some cases, cytokine levels
were determined by Luminex assay (Bio-Plex ProTM Human Th17
Cytokine Assays, Bio-Rad Laboratories, CA, USA). Fibroblast
culture supernatants were analyzed using standard IL-6 and IL-8
Biolegend ELISA kits and a luminex assay (R&D) for CXCL1,
CXCL5, and CCL20 levels. Cell-free serum and synovial fluid
samples were analyzed using Platinum kits for IL-17A and IL-17F
(eBioscience) and a Luminex assay (Bio-Plex ProTM Human
Th17 Cytokine Assays, Bio-Rad Laboratories) for IL-1β and
IL-23. All analyses were performed according to manufacturer’s
instructions.
Statistical analysis
Statistical differences were calculated using Prism 7.0 software
(Graphpad, San Diego, CA). A D’Agonisto and Pearson omnibus
normality test was followed by statistical significance testing using
the appropriate tests as described in the figure legends. Data sets
with n values< 8 were tested non-parametrically. P-values< 0.05
were considered statistically significant.
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